VERU250103P1500
- 0.89
- 0.000.00%
Veru Inc Newsroom
Veru Sells Female Condom Business to Riva Ridge Capital for $18 Million
Veru Inc. Sells FC2 Female Condom Business for $18 Million to Focus on Biopharmaceutical Drug Development
Express News | Veru Inc - Expects $12.5 Million Proceeds After Deductions From Fc2 Sale
Express News | Veru Inc - to Reduce Headcount by Approximately 90% After Fc2 Sale
Express News | Veru Announces the Sale of the Fc2 Female Condom® (Internal Condom) Business
H.C. Wainwright Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $3
Veru Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Veru Analyst Ratings
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
Veru Inc | 10-K: FY2024 Annual Report
The Past Three Years for Veru (NASDAQ:VERU) Investors Has Not Been Profitable
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Some Veru Inc. (NASDAQ:VERU) Shareholders Look For Exit As Shares Take 34% Pounding
Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5
Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek
Express News | Veru Inc - Topline Results From Phase 2B Quality Trial Expected in January 2025
Express News | Veru Inc - Enobosarm Generally Well-Tolerated With No Increase in Gastrointestinal Side Effects
Express News | Veru To Present Meta-Analysis of 4 Previous Randomized Clinical Trials That Support Potential Of Enobosarm To Optimize Weight Loss At ObestiyWeek
"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.
Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.